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ViceCT and whiceCT 
for simultaneous high‑resolution 
visualization of craniofacial, 
brain and ventricular anatomy 
from micro‑computed tomography
Sergi Llambrich1,2, Jens Wouters1,2, Uwe Himmelreich1,2, Mara Dierssen3,4, James Sharpe5, 
Willy Gsell1,2, Neus Martínez‑Abadías6 & Greetje Vande Velde1,2*
Up to 40% of congenital diseases present disturbances of brain and craniofacial development resulting 
in simultaneous alterations of both systems. Currently, the best available method to preclinically 
visualize the brain and the bones simultaneously is to co‑register micro‑magnetic resonance (µMR) 
and micro‑computed tomography (µCT) scans of the same specimen. However, this requires expertise 
and access to both imaging techniques, dedicated software and post‑processing knowhow. To provide 
a more affordable, reliable and accessible alternative, recent research has focused on optimizing a 
contrast‑enhanced µCT protocol using iodine as contrast agent that delivers brain and bone images 
from a single scan. However, the available methods still cannot provide the complete visualization 
of both the brain and whole craniofacial complex. In this study, we have established an optimized 
protocol to diffuse the contrast into the brain that allows visualizing the brain parenchyma and the 
complete craniofacial structure in a single ex vivo µCT scan (whiceCT). In addition, we have developed 
a new technique that allows visualizing the brain ventricles using a bilateral stereotactic injection of 
iodine‑based contrast (viceCT). Finally, we have tested both techniques in a mouse model of Down 
syndrome, as it is a neurodevelopmental disorder with craniofacial, brain and ventricle defects. The 
combined use of viceCT and whiceCT provides a complete visualization of the brain and bones with 
intact craniofacial structure of an adult mouse ex vivo using a single imaging modality.
Brain dysmorphologies are associated with malformations of the craniofacial skeletal system in 30–40% of con-
genital disorders 1–4. This is the case in holoprosencephaly, micro- and macrocephaly, Apert syndrome, Down 
syndrome, Williams syndrome, Rett syndrome and Fragile X syndrome 5–10, with varying degrees of severity of 
craniofacial and brain alterations. Experimental mouse models for these disorders are typically used to investigate 
the mechanisms underlying brain and skull malformations 1.
Since the brain and the face have an intimately integrated development and maintain a continuous physical 
and molecular interplay through common signaling pathways 2, it is crucial to analyze the malformations in both 
systems simultaneously. However, these investigations are hampered by the lack of a technique to visualize the 
complete anatomy of the brain and the craniofacial bones in a single scan at sufficiently high resolution. Different 
tomographic methods are available to image the brain or the skull separately.
In vivo methods such as micro-magnetic resonance imaging (µMRI) provide non-invasive tomographic 
images of the brain anatomy in  3D11. However, the resolution (≈ 50 to 100 µm3) is sometimes not sufficient to 
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visualize in detail small neuroanatomical structures of interest like the hippocampus 12. The resolution is limited 
by the acquisition times necessary to avoid adverse effects of long exposure to anesthesia 13. The alternative is 
ex vivo imaging, where scanning time is no longer a constraint and microscopic examination provides detailed 
imaging at high resolution. Nevertheless, a limitation of such ex vivo imaging techniques is the need to dissect 
the brain from the skull and/or to section the tissue, which disrupts their original 3D structure. Moreover, all 
ex vivo techniques have the common drawback that the ventricles significantly shrink or collapse after euthanasia 
14–16, precluding evaluation of ventricular anatomy.
To image the craniofacial complex in 3D, the gold standard is micro-computed tomography (µCT) 17. This 
is a non-destructive technique that produces high-resolution images (≈ 35 to 50 µm isotropic) of mineralized 
tissue using short scanning times and low radiation exposure in vivo 18, as well as ultra-high resolution images 
(≈ 1 to 9 µm) using longer exposure ex vivo 19.
To visualize the brain and the skull simultaneously, the most common approach is to scan each structure 
separately using µMRI for the brain and µCT for the skull, and then co-registering both scans 20,21. However, 
this results in a time and cost-demanding pipeline requiring multiple acquisitions, expertise in and access not 
only to both imaging techniques, but also to advanced image processing and co-registration software. In this 
dual-modality setup, the need of µMRI to visualize the brain is associated with manifold higher infrastructure 
and operational costs than µCT.
Diffusible iodine-based contrast-enhanced computed tomography (diceCT) could provide an alternative 
to image the brain and the craniofacial complex within a single acquisition. DiceCT is a time and cost efficient 
ex vivo imaging procedure that uses iodine as contrast agent, thereby allowing the visualization of both skeletal 
and soft tissues at the high resolution from a µCT scan 22–27. However, diceCT procedures for adult mice only 
manage to deliver the contrast to the brain at the expense of the integrity of the craniofacial complex. In the 
approaches where diceCT has been applied to visualize the mouse and rat brain, the skull was completely removed 
28–31. In others, where adult mouse brains were imaged within the skull, several parts of the craniofacial complex 
were removed to enhance the diffusion of iodine-potassium iodide  (I2KI) into the brain 32. Alternative protocols 
have explored the use of selectively perfusable iodine-based contrast-enhanced computed tomography (spiceCT) 
to administer contrast to the entire mouse body leaving the entire anatomy intact including the craniofacial 
structure, but this strategy does not manage to provide contrast into the brain 33. Imaging protocols using other 
contrast agents such as phosphotungstic acid (PTA) have enabled the visualization of bone and soft tissue from 
µCT scans with minimal shrinkage 34, but have not yet been optimized for adult mice, are more costly and require 
more elaborated sample processing. Finally, the brain ventricles are not visible in any of these approaches, which 
implies an extra limitation for the neurodegenerative and neurodevelopmental disorders research fields, where 
the ventricular anatomy or volume are important biomarkers 35–38.
We therefore set out to develop a novel approach that allows to simultaneously visualize and phenotype the 
anatomy of the brain or the ventricles and craniofacial structures, from a single modality using high-resolution 
µCT acquisition. We have tested different protocols for contrast delivery, such as transcardial perfusion and 
diffusion of iodine solution to obtain homogeneous contrast into the brain parenchyma while maintaining the 
craniofacial structures intact. In addition, we have developed a new technique that uniquely allows visualiza-
tion of the mouse brain ventricles without collapsing, maintaining intact the brain, head and even whole body. 
Finally, to demonstrate the potential of these novel imaging techniques we applied them in the Ts65Dn mouse 
model of Down syndrome, an example of a congenital disorder where the craniofacial complex, the brain, and 
the ventricles are simultaneously affected 10,39–44.
Results
Transcardial perfusion for iodine‑based contrast delivery to the brain. First, we explored dif-
ferent approaches to deliver the contrast to the brain via transcardial perfusion while modulating blood–brain 
barrier (BBB) permeability in wildtype (WT) mice. In all our experiments, Lugol’s solution was used as the 
source of iodine. We assessed different protocols adjusting the order, timing and proportion of perfused reagents 
(Supplementary Table S1). We then scanned the adult mice with whole-body µCT.
The whole craniofacial complex was visible in all the µCT scans, but none of the transcardial perfusion pro-
tocols resulted in homogeneous brain contrast (Supplementary Figure S1). Perfusing the Lugol’s solution for 
50 min and fixing the tissue by incubating the sample in 4% paraformaldehyde (PFA) for 48 h did not provide 
contrast in the brain, but increased contrast in soft tissues such as cardiac muscles, pericardial structures and 
lungs (Supplementary Table S1 G; Supplementary Figure S2). We could achieve patchy brain contrast when 
perfusing first with Lugol’s solution during 20 min (Supplementary Table S1 F; Supplementary Figure S1 F) and 
when disrupting the BBB with mannitol (Fig. 1; Supplementary Table S1 H).
Whole head iodine‑based contrast‑enhanced computed tomography (whiceCT). In a second 
approach, we developed an iodine-diffusion technique to visualize the brain parenchyma with minimal shrink-
age and without removing the facial skeleton. We explored the optimization of different parameters to facilitate 
the contrast diffusion into the mouse brain. We removed the external soft tissue of the severed mouse heads and 
drilled two burr holes on the parietals to facilitate diffusion. Then, the heads were incubated in Lugol’s solution 
for different periods of time and at different refreshment rates. To establish the optimal staining conditions, we 
scanned the samples several times during this process with µCT.
In a first optimization round, the mouse heads were fixed in PFA during two days and incubated with 30 mL 
of Lugol’s solution that was renewed six times during 21 days (at days 2, 4, 9, 12, 18 and 21) (Fig. 2 top row). 
The whiceCT scans produced detailed images of both the whole skull and the brain parenchyma after 18 days of 
sample incubation. The contrast enhancement was sufficient to visualize brain structures such as the cerebellum, 
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olfactory bulbs and hippocampus. However, the brain presented with significant shrinkage (Fig. 2 top row, 
white arrows). Incubating the samples until day 21 improved the contrast at the core of the brain, but worsened 
shrinkage (Fig. 2 top row).
To minimize brain shrinkage, we increased the fixation time in PFA from two to three days, incubated the 
samples within a higher volume of Lugol’s solution (from 30 to 45 mL) and limited changing the Lugol’s solu-
tion only to the scanning days (days 4, 18 and 21) (Fig. 2 bottom row). The µCT scans showed that by day 18 the 
contrast in the different brain structures (cerebellum, olfactory bulbs and hippocampus) optimally improved 
while the brain shrinkage was minimal (Fig. 2 bottom row; Video 1 with 3D visualization of a whiceCT scan). 
Incubating the samples until day 21 improved the contrast at the most inner regions of the brain, but worsened 
shrinkage (Fig. 2 bottom row, white arrows), indicating that incubating the samples until day 18 is the most 
optimal for improved contrast and reduced shrinkage.
We have named this new optimized technique as “whole head iodine-based contrast-enhanced CT” or 
“whiceCT”. WhiceCT is a useful method to visualize the brain parenchyma with minimal shrinkage together 
with the craniofacial structures in a single µCT scan.
To cross-validate the whiceCT protocol with the gold standard for brain imaging, we scanned six WT mice 
with in vivo µMRI and subsequently performed whiceCT. Upon visual comparison, the tomographic images 
showed similar contrast and edge definition of brain anatomical regions in both imaging techniques (Fig. 3A). 
Except for the ventricles, which were not visible from the whiceCT scan due to their collapse after sacrifice, the 
same brain structures could be identified in whiceCT and µMR scans without obvious signs of shrinkage, such as 
the isocortex, hippocampus, striatum, colliculi, olfactory bulbs and cerebellum (Fig. 3A, Supplementary Figure 
S3). Additionally, whiceCT scans allowed to visualize the skull, which was not visible from the µMRI. WhiceCT 
presented minimal shrinkage at the anterior ventral part of the brain, visualized as a minimal gap between the 
brain and the skull (Supplementary Figure S3). More extended shrinkage was only detected in some mice at 
the level of the cerebellum. A possible explanation could be that this posterior region of the brain is closest to 
the neck surgical cut used to severe the heads and was therefore more exposed to Lugol’s than the internal and 
anterior regions of the brain (Supplementary Figure S3).
Figure 1.  Whole-body µCT upon transcardial perfusion of Lugol’s solution after blood–brain barrier 
disruption results in contrast enhancement in body organs and non-homogeneous contrast in the brain. (A) 
Sagittal view of the upper mouse body, perfused according to Supplementary Table S1 protocol H. Contrast 
enhancement could be detected in the brain and several body organs, such as bowels (b), liver (l) and heart (h). 
(B) Axial and (C) coronal µCT view of the head, visualizing the skull and patchy contrast enhancement in the 
brain parenchyma. The scans reveal that the skull is visible and the contrast was delivered into the brain, but the 
staining was not homogeneous.
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To perform more specific comparisons regarding the brain region where we observed shrinkage, we seg-
mented the cerebellum from both the µMRI and µCT scans and compared the resulting 3D reconstructions 
regarding their shape, resolution and volume. The segmented cerebellums were similar in shape (Fig. 3B). The 
reconstruction from the whiceCT protocol showed increased detail due to the higher resolution of µCT (51.62 µm 
for 11 min scan time) as compared to the resolution of the in vivo µMRI (156 µm for 20 min scan time) (Fig. 3B). 
To further evaluate the agreement between whiceCT and µMRI, we performed a Bland Altman test that assessed 
the differences in cerebellar volume measured by the two methods. The results revealed that the differences were 
consistent for low and high cerebellar volumes, as the points were equally distributed along the x-axis (Fig. 3C). 
However, the Bland Altman test indicated that the cerebellum volume estimated from whiceCT scans was consist-
ently lower than the volume measured from µMRI (Fig. 3C). On average, there was a difference between methods 
of − 20.21% of the mean cerebellar volume. Individual differences between methods could range from − 11.29 
to − 29.12% of the mean cerebellar volume, considering the 95% confidence intervals. We found a maximum 
volume difference of − 14.41  mm3, which represented 24.34% of the mean cerebellum volume (Fig. 3C). These 
differences in cerebellar volume could possibly be attributed to a certain degree of tissue shrinkage during the 
sample processing procedure. However, some differences could also arise from differences in the resolution 
in the two scanning methods, as µCT has higher resolution than µMRI, produces smaller voxel sizes and this 
may also affect the segmentation. Overall, the results from the Bland Altman test performed in the brain region 
most affected by shrinkage provide a reliable quantification of the maximum difference in volume that could be 
expected between µMRI and whiceCT.
Figure 2.  WhiceCT results across the sample processing pipeline. Top row: µCT Scans obtained after the 
mouse heads were immersed in Lugol’s solution for 4, 12, 18 and 21 days; with the Lugol’s solution refreshed 
as indicated in the timeline. µCT at day 4 confirmed correct positioning of drill holes and contrast diffusing 
into the brain parenchyma. By day 18, contrast enhancement was sufficient to visualize brain structures such 
as the cerebellum (cb), olfactory bulbs (o) and hippocampus (h), but some shrinkage was observed (white 
arrowheads). Incubating the sample until day 21 did not further increase the contrast and worsened the 
shrinkage. In a subsample of mouse heads, the Lugol’s solution was not refreshed at day 2, which did not result 
in any observable difference (not shown). Bottom row: Scans obtained after the mouse heads were immersed 
in Lugol’s solution for 4, 18 and 21 days with the Lugol’s solution only renewed at each scan time. µCT 
showed incomplete contrast diffusion into the brain by day 4. By day 18, minimal shrinkage was observable 
around the cerebellum while the contrast was optimal to visualize the cerebellum, the olfactory bulbs and the 
hippocampus among other brain structures. Finally, incubating the samples for three more days did not further 
improve contrast and caused further shrinkage. The bottom framed protocol is the optimal proposed pipeline 
for visualizing the intact craniofacial structures and brain parenchyma with minimal shrinkage and optimal 
contrast from a single µCT at day 18.
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Finally, our whiceCT protocol can provide ultra-high-resolution images of the brain and skull in comparison 
with a high-resolution ex vivo µMRI scan that only visualizes the brain. To illustrate this potential, a mouse head 
was scanned with whiceCT at an isotropic resolution of 9 µm in 3 h and 3 min and was compared with another 
mouse head scanned with gadolinium-enhanced ex vivo µMRI at an isotropic resolution of 62.5 µm in 12 h and 
17 min. Qualitative comparison of the tomographic images of the ultra-high resolution whiceCT (Fig. 4 top) and 
contrast-enhanced ex vivo µMRI (Fig. 4 bottom), showed that both ultra-high resolution whiceCT and ex vivo 
µMRI showed the hippocampus and the striatum in the axial view (Fig. 4A,D). In the coronal view (Fig. 4B,E), 
both techniques were able to visualize the hippocampus and distinguish the Ammon’s horn and dentate gyrus. In 
Figure 3.  WhiceCT compared to in vivo µMRI. (A) Reconstructed images of whiceCT (left) and in vivo µMRI 
(right). Similar edge definition can be observed for both µCT as µMRI in the brain parenchyma in the axial 
(top), coronal (middle) and sagittal (bottom) planes and the same structures can be visualized, except for the 
ventricles, as they are collapsed in the ex vivo scan. For example, the striatum (s), hippocampus (h), isocortex 
(x), thalamus (t), olfactory bulbs (o), cerebellum (cb) and colliculi (c) are visible. (B) Volume renderings of 
the cerebellum segmented from whiceCT (left) and in vivo µMRI (right). Note the similarity in shape and the 
difference in voxel size. (C) Bland–Altman test of the agreement between cerebellum volume obtained with 
whiceCT and µMRI (n = 6). The densely dotted line at 0 in the Y axis represents the line of equality. Upper and 
lower loosely dotted lines represent the 95% limits of agreement. The central loosely dotted line represents the 
bias. Shaded area represents 95% confidence interval limits for the bias. The average shift represented − 20.21% 
of the mean cerebellum volume, calculated as the ratio between the bias (11.49  mm3) and the mean volume of 
the cerebellum (56.86  mm3). The differences between the two measurements over the mean cerebellum volume, 
calculated as the ratio between the 95% limits of agreement of the bias (− 6.42  mm3 and − 16.56  mm3) and the 
mean volume of the cerebellum (56.86  mm3), can range from − 11.29% to − 29.12%. Negative values indicate 
lower volumes obtained with µCT. The percentage of difference between methods is shown for each comparison.
6
Vol:.(1234567890)
Scientific Reports |        (2020) 10:18772  | https://doi.org/10.1038/s41598-020-75720-3
www.nature.com/scientificreports/
the sagittal view (Fig. 4C,F) both images show the isocortex and corpus callosum with the MR images showing 
better contrast in the hippocampus but the µCT images having better contrast in the thalamus.
Overall, the whiceCT protocol produced detailed images of the entire craniofacial structure as well as brain 
structures at shorter scanning times as compared with in vivo and ex vivo µMRI. Moreover, smaller structures 
could be visualized increasing the resolution and acquiring more projections resulting in a scan time of 3 h and 
3 min, achieving higher resolution and less noise than ex vivo µMRI scan in 12 h and 17 min (Fig. 4).
Ventricle injection contrast‑enhanced CT (viceCT). As whiceCT and ex vivo µMRI are techniques 
where imaging is performed after the mice have been euthanized, the ventricles collapse due to the loss of cer-
ebrospinal fluid pressure and, thus, the original morphology of the brain ventricles is lost. To enable the evalua-
tion of ventricular morphology, we developed a novel protocol to visualize the ventricles before they collapse by 
directly injecting the contrast into the ventricles under terminal anesthesia. We explored an optimal approach 
to perform stereotactic injections of the contrast into the lateral brain ventricles of terminally anesthetized mice 
by changing the volume of Lugol’s solution and the injection location. To assess whether these staining protocols 
resulted in homogeneous contrast in the ventricular system immediately after contrast injection, the mice were 
scanned with µCT with optimized scanning parameters (Supplementary Table S2).
Figure 4.  Images obtained with ultra-high resolution whiceCT (9 µm) compared with ex vivo µMRI (62.5 µm). 
Top: images obtained with an ultra-high-resolution whiceCT, with zoom-in to detailed structures of interest, 
such as the striatum (s), hippocampus (h), Ammon’s horn (ah), dentate gyrus (dg), isocortex (x), corpus 
callosum (cc) and thalamus (t). Bottom: images obtained using a contrast-enhanced µMRI with similar zoom-in 
details. Panels A and D: axial planes, panels B and E: coronal planes and panels C and F: sagittal planes.
7
Vol.:(0123456789)
Scientific Reports |        (2020) 10:18772  | https://doi.org/10.1038/s41598-020-75720-3
www.nature.com/scientificreports/
First, we performed a unilateral stereotactic injection of 100 µL of Lugol’s solution into the right lateral ven-
tricle of the mice. Although the brain ventricles were visible on the µCT scans, the contrast was not confined to 
the ventricular system and the high pressure during contrast administration could have altered the ventricular 
anatomy (Supplementary Figure S4). With an injected volume of Lugol’s solution of 50 µL, the contrast remained 
confined within the right lateral ventricle, the third and fourth brain ventricles and the cerebral aqueduct and 
no anatomical alterations could be observed (Fig. 5A, left). However, the contrast was not homogeneously 
distributed in the left lateral brain ventricle. To visualize simultaneously both the right and left lateral brain 
ventricles, we next performed a bilateral stereotactic injection of 40 µL of Lugol’s solution into each of the left 
and right lateral ventricles. The resulting µCT showed that the contrast was confined and uniformly distributed 
in both lateral ventricles, the third and the fourth ventricles and the cerebral aqueduct (Fig. 5A, right; Video 2 
with 3D visualization of a viceCT scan). Moreover, the whole-body scan of the intact mouse allowed to evaluate 
the ventricle morphology in context of the cranium and the whole skeleton. We named this optimized technique 
as ‘ventricle injection contrast-enhanced CT’ or ‘viceCT’.
We quantified the contrast enhancement produced by iodine in the ventricles by viceCT as the difference in 
radiodensity of the brain parenchyma and the ventricles. The average radiodensity in the brain parenchyma was 
180 ± 23 HU and 1,311 ± 304 HU in the brain ventricles, which resulted in a contrast enhancement of 1,131 ± 281 
HU (n = 6) (Supplementary Table S4).
To evaluate the stability of the contrast over time for viceCT, we performed a bilateral ventricular stereotactic 
contrast injection and scanned the mouse at three different time points: immediately after injection, 50 min 
after injection, and 21 h after injection. Qualitative evaluation of the scans showed that the contrast faded over 
time and was no longer detectable after 21 h (Fig. 5B). The quantitative evaluation confirmed that the ventricles’ 
radiodensity decreased from 1,573 HU in the first timepoint to 1,487 HU in the second and to 861 HU in the 
third (Supplementary Table S4). This indicates that the mice should be scanned within one hour after stereotactic 
injection to benefit from maximal contrast enhancement.
To compare the image quality and the level of contrast enhancement of viceCT and µMRI, we computed 
the signal-to-noise ratio (SNR) and the contrast-to-noise ratio (CNR) of mouse heads imaged with µMRI and 
subsequently with viceCT (Fig. 5C; Supplementary Table S4). In the brain parenchyma, the SNR was comparable 
for viceCT (24.87 ± 6.74, n = 6) and µMRI (28.66 ± 10.02), whereas in the ventricles the mean SNR was lower for 
viceCT (21.30 ± 5.04) than for µMRI (41.16 ± 12.69). Nevertheless, all SNR values were high above 5 and thereby 
met the Rose criterion, which is currently the most used reference detectability  measure45,46. Moreover, the CNR 
for the ventricles was superior for viceCT (22.47 ± 2.95) as compared to µMRI (12.50 ± 4.24), and overall high 
for both modalities, making it possible to reconstruct the morphology of the brain ventricles from both types 
of scans.
We next cross-validated the ability to segment the ventricles from viceCT using in vivo µMRI as a refer-
ence. Gross visual comparison of the brain ventricles showed overall similar shapes, but more detailed inspec-
tion revealed differences in the shape of the brain ventricles segmented from viceCT and in vivo µMR scans 
(Fig. 5D). Whereas µMRI showed a more complete segmentation of the ventral part of the lateral ventricles, 
viceCT provided greater detail in the reconstructions of the fourth ventricle and cerebral aqueduct. Moreover, 
due to smaller voxel size, viceCT provided better spatial resolution, resulting in more detailed images within 
shorter scan time (Fig. 5D).
Finally, we investigated the agreement between the volumes of the entire ventricular system and the lateral 
ventricles segmented with µMRI and viceCT using a Bland Altman test. The results indicated that the ventricular 
and lateral ventricles’ volume estimated from viceCT and µMRI scans were similar and consistent for low and 
high ventricular volumes (Fig. 5E,F). On average, there was a non-significant difference between methods of 
5.39% of the mean ventricle volume, as the line of equality fell within the 95% confidence interval of the bias. 
Individual differences between methods could range from − 15.69 to 26.40% of the mean ventricle volume, 
considering the 95% confidence intervals. We found a maximum volume difference of 2.73  mm3, which rep-
resented 20.71% of the mean ventricle volume (Fig. 5E). For the lateral ventricles, the average difference of the 
mean lateral ventricles’ volume of 2.59% was not significant. Individual differences between methods could 
range from 36.42 to 41.59% of the mean lateral ventricles’ volume and the maximum volume difference found 
was 3.71  mm3 (40% of the mean lateral ventricles’ volume) (Fig. 5F). This higher variation is mainly due to the 
discrepancy in measurements between viceCT and µMRI in only one mouse, as the other five mice presented 
low differences between viceCT and µMRI in the estimation of the lateral ventricles’ volume and thus consistent 
results between viceCT and µMRI (Fig. 5F). Our results thus suggest that viceCT is a useful technique for the 
analysis of both the entire ventricular system and the lateral ventricles.
Comparison of viceCT and whiceCT for skull analysis. We have developed two novel techniques that 
allow visualizing at high resolution the brain ventricles (viceCT) and the brain parenchyma (whiceCT) together 
with the skull from a µCT scan. Both techniques allow to visualize the morphology of the skull. The comparison 
between the 3D surface skull reconstructions obtained with viceCT and whiceCT showed that for most regions 
of the skull, viceCT and whiceCT scans produced similar outcomes, with minimal differences between them 
(Fig. 6, top and middle). More substantial differences were only localized in those regions where some soft tissue 
was still attached to the skull in the whiceCT scan (Fig. 6, top and middle). The comparison of the tomographic 
images of the snout showed that a thin, low-density bone such as the ethmoid cannot be clearly visualized using 
whiceCT, but is visible in the viceCT scan and clearly defined in the ultra-high resolution whiceCT image (Fig. 6, 
bottom). These results demonstrate that both techniques can be used for the evaluation of the skull morphology 
and underscore that for detailed qualitative and quantitative skull analysis such as with Geometric Morphomet-
rics, the use of whiceCT requires careful manipulation of the sample to completely extract the soft tissue without 
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damaging or scratching the skull. Therefore, the use of viceCT is recommended to perform skull morphometric 
analyses, as a more practical, precise and reliable procedure to image the skull, as we illustrate in the next section.
Applications of viceCT and whiceCT. To show the capability of our approach towards phenotyping mouse 
models of conditions that require integrated evaluation of the craniofacial and brain morphology including the 
ventricles, we applied the combination of viceCT with whiceCT to evaluate ventricular anatomy and whole-brain 
anatomy within an intact craniofacial skeleton in a trisomic (TS) mouse model of Down syndrome 47.
Specifically, we applied both viceCT and whiceCT to the same mice, to assess whether these combined tech-
niques are able to pick up major phenotypic differences induced by genetic differences in euploid and trisomic 
mice 10,39–44, as well as differences induced by pharmacological modulation by green tea extracts containing 
epigallocatechin-3-galate (GTE-EGCG). GTE-EGCG has been used as a modifying agent of the morphology of 
the brain, ventricles and skull, as it is known to mediate brain and craniofacial development in this mouse model 
for Down syndrome 41,48–50. An image for each condition is shown in Supplementary Figure S5.
WhiceCT scans visualized single brain structures, such as the hippocampus, the cerebellum, the isocortex and 
the olfactory bulbs. The efficient contrast enhancement allowed us to segment the cerebellum for comparison 
among WT and TS mice, as it is a structure known to be severely affected in trisomic Down syndrome mouse 
models 51–53, and to assess whether GTE-EGCG produced any further difference in these groups of mice. Both 
untreated and treated TS mice showed relatively smaller cerebellar volume as compared with WT euploid mice, 
although the differences did not reach the significance level considering the high variation in cerebellar volume 
in all the mouse groups and the small sample sizes (Fig. 7A).
ViceCT scans visualized the outline of the ventricles and the brain, which was clearly defined by the endocra-
nial space of the skull, allowing straightforward segmentation of these structures. ViceCT detected a significant 
increase in the whole brain volume of the TS treated group as compared with the WT untreated group, showing 
the capability of this method to detect differences due to genotype and pharmacological intervention (Fig. 7B). 
Moreover, viceCT detected that the WT and TS treated groups showed higher variation in the ventricular volume 
than the untreated WT mice (Fig. 7C).
To perform a quantitative skull shape comparison between experimental mouse groups, we used the high 
resolution viceCT scans, for the reasons explained above. We recorded the 3D coordinates of 27 anatomical land-
marks on the 3D skull reconstructions resulting from the viceCT scans. Following a Geometric Morphometric 
approach, we explored skull morphological variation using a Principal Component Analysis (PCA) after the 
Procrustes superimposition of the landmark coordinates. Results showed that WT and TS mice were separated 
in the morphospace along PC1, indicating that most skull morphological variation in the sample is due to dif-
ferences in genotype (Fig. 7D). The shape differences associated with PC1 indicated that TS mice (positive PC1 
scores) showed wider skulls with retracted faces in comparison to WT mice (negative PC1 scores), in which the 
relative positions of the anatomical landmarks represented in the wireframes are associated with slender skull 
shapes (see Supplementary Figure S6 for anatomical reference). Thus, the shape changes represented by PC1 
correspond to the main clinical features associated with Down syndrome, such as brachycephaly and midfacial 
Figure 5.  Qualitative and statistical evaluation of the ventricular system obtained with viceCT compared 
to in vivo µMRI. (A) Images obtained using a unilateral (left column) and a bilateral (right column) 
ventricular injection of Lugol’s solution, where enhanced contrast can be observed in the ventricles in the axial 
(top row), coronal (middle row) and sagittal (bottom row) planes. (B) Time course visualization of a mouse 
brain processed with viceCT at 0 min, 50 min and 21 h post injection (p.i.). In the scan acquired 0 min p.i., 
the ventricles were visible and clearly distinguishable from the brain parenchyma. In the scan acquired 50 min 
p.i, the delineation of the ventricles was less pronounced. In the scan acquired 21 h p.i., the contrast was no 
longer detectable on µCT, indicating that the ventricular contrast enhancement faded over time. (C) Images 
obtained using viceCT (left column) and in vivo µMRI (right column) showed similar contrast enhancement 
in the ventricles, observed in the axial (top row), coronal (middle row) and sagittal (bottom row) planes. (D) 
3D surface rendering of the segmented ventricles obtained from viceCT (left column) and in vivo µMRI (right 
column) showed similar shapes, but detailed inspection revealed differences in the shape of the ventral part of 
the lateral ventricles, the fourth ventricle and the cerebral aqueduct. (E) Bland–Altman test representing the 
difference in ventricle volume obtained with viceCT and µMRI (n = 6). Densely dotted line at 0 in the Y axis 
represents the line of equality. Upper and lower loosely dotted lines represent the 95% limits of agreement. 
Central loosely dotted line represents the bias. Shaded area represents 95% confidence interval limits for the 
bias. The relative average bias represented 5.39% of the mean ventricle volume, calculated as the ratio between 
the average bias (0.71  mm3) and the mean volume of the ventricle (13.18  mm3). The differences between the 
two measurements over the mean ventricle volume, calculated as the ratio between the 95% limits of agreement 
of the bias (− 2.06  mm3 and 3.48  mm3) and the mean volume of the ventricle (13.18  mm3), can range from 
− 15.62% to 26.40%. Negative values indicate lower volumes obtained with µCT. The percentage of difference 
is shown for each comparison. (F) Bland–Altman test representing the difference in the lateral ventricles 
volume obtained with viceCT and µMRI (n = 6). The relative average bias represented 2.59% of the mean 
ventricle volume, calculated as the ratio between the average bias (0.24  mm3) and the mean volume of the 
lateral ventricles (9.28  mm3). The differences between the two measurements over the mean lateral ventricles 
volume, calculated as the ratio between the 95% limits of agreement of the bias (− 3.38  mm3 and 3.86  mm3) 
and the mean volume of the lateral ventricles (9.28  mm3), can range from − 36.42% to 41.59%. Negative values 
indicate higher volumes obtained with µMRI. The percentage of difference between methods is shown for each 
comparison.
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 retraction54. As shown in Fig. 7E, the skulls in TS mice (red surface) are typically shorter, wider and present 
substantially less developed faces as compared to WT mice (yellow surface). Significant differences due to phar-
macological treatment were not detected in this analysis, as WT untreated and treated mice overlapped in the 
negative extreme of PC1, and TS untreated and treated mice remained in the positive extreme of PC1 (Fig. 7D). 
Further vice- or whiceCT analyses with higher sample sizes should be used to assess a potential effect of phar-
macological modulation in TS mice.
Discussion
To resolve the current need for a methodology to accurately phenotype the brain, ventricular system and crani-
ofacial anatomy in small animal models, we designed several strategies to visualize the brain anatomy and the 
entire craniofacial complex with high resolution using a single imaging modality. As µCT has the ability to 
provide excellent visualization of the craniofacial bones with high resolution but needs contrast enhancement 
to enable the visualization of brain anatomy, we investigated three approaches involving delivery of a contrast 
agent, i.e. Lugol’s solution, into the mouse brain.
A first approach based on transcardial perfusion of contrast resulted in successful whole-body contrast 
enhancement leaving the craniofacial structures intact. However, this technique needs to be accompanied with 
blood–brain barrier disruption in order to achieve iodine-based contrast agent delivery into the brain paren-
chyma, as already pointed out by previous findings 33. Even then, this approach resulted in patchy enhancement 
of brain anatomy (Fig. 1).
We developed two other novel contrast infusion approaches that successfully achieved specific ventricular 
and whole-brain contrast enhancement and subsequent visualization with µCT. We named these techniques as 
“ventricle injection contrast-enhanced CT” (viceCT) and “whole head iodine-based contrast-enhanced computed 
tomography” (whiceCT).
In viceCT, the contrast agent is injected stereotactically and bilaterally into the ventricular system under ter-
minal anesthesia. This optimized protocol resulted in successful visualization of the brain ventricular system in 
the context of the intact whole body and craniofacial structures using fast high-resolution ex vivo µCT (Fig. 5). 
A remarkable novel asset to this approach is that it enables the evaluation of ventricular volume and morphol-
ogy with minimal loss of cerebrospinal fluid pressure, as the images are obtained short after euthanasia. Brain 
shrinkage due to sample processing was not a significant issue. ViceCT produced similar visualizations of the 
ventricles as compared to in vivo µMRI, although viceCT did not visualize the most ventral part of the ventri-
cles. Bland Altman analysis revealed a disagreement of 5.39% of the mean ventricle volume derived from µMRI 
Figure 6.  Comparison of the skull obtained from whiceCT and viceCT. Top and middle: comparison of the 
3D skull reconstructions segmented from viceCT and whiceCT scans of the same mouse. Left: superposition 
by rigid registration of the two reconstructions, as obtained with viceCT (yellow) and whiceCT (red). Central: 
heatmap showing the differences between a viceCT and a whiceCT scans, with red areas indicating where the 
largest differences occur. Right: differences between viceCT and whiceCT displayed as a vector map. Bottom: 
axial tomographic images of the snout of a mouse obtained with viceCT (left) whiceCT (middle) and ultra-high 
resolution whiceCT (right).
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Figure 7.  ViceCT combined with whiceCT enable quantification of brain regions’ volume and skull shape to 
evaluate genotype and pharmacological effects in a Down syndrome mouse model. (A) WhiceCT-based 3D 
surface rendering of the cerebellum and grouped scatter plot comparing the cerebellar volume normalized to 
the whole brain volume of wildtype (WT) and trisomic (TS) mice, pharmacologically modulated or not with 
GTE-EGCG. (B) ViceCT-based 3D surface rendering of the brain and grouped scatter plot of the relative whole 
brain volume. (C) ViceCT-based 3D surface rendering of the ventricular system and grouped scatter plot of the 
relative ventricle volume. Error bars represent standard error of the mean in all scatter plots. (D) Scatter plot 
assessing skull shape variation from a Principal Component Analysis (PCA) based on the landmarks described 
in Supplementary Table S3. In the scatterplot of the first two PC axes, which together explain 58.35% of the 
variation, each point represents the skull shape of one individual and experimental groups of mice are outlined 
using convex hulls, except for the TS untreated mouse. Close proximity between groups indicates similar skull 
phenotypes, while separation indicates dissimilarity. Wireframes displaying skull morphologies along PC1 of 
the PCA analysis based on the global skull configuration of landmarks (Supplementary Figure S6). Dark blue 
wireframes represent the morphology associated with the specimens located on the negative (WT mice, left) 
or positive (TS mouse, right) extreme of PC1 in comparison to the mean shape of the sample (red wireframe). 
Note that the wireframes are exaggerated and correspond to the shapes that would be seen at values of 0.1 and 
− 0.1 in PC1 to better illustrate the differences in shape. (E) Comparison of the 3D surface rendering of a WT 
and a TS mouse segmented from viceCT scans. Left images show two representative skulls overlaid by rigid 
registration with the WT mouse in yellow and the TS mouse in red, highlighting that TS mice (red) present 
with shorter and wider skulls (brachycephaly) and less developed faces (facial retraction), which correspond 
to the clinical features associated with Down syndrome in humans. Central images display a heatmap showing 
the dissimilarities between a WT and a TS mouse with red areas representing higher differences. Right images 
display a vector map showing in red the largest dissimilarities between WT and TS mice. WT Untreated n = 4, 
WT Treated n = 4, TS Untreated n = 1, TS Treated n = 4.
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versus viceCT (Fig. 5, E), a difference that may not be biologically relevant. Significant differences in ventricular 
volume are typically at least 10%, as detected in experiments using µMRI in adult mice to study neurodegenera-
tion, brain inflammation or Down syndrome 43,55,56. Using viceCT scans, it is also possible to perform detailed 
shape analysis of the skull, as the skeleton remains intact except for the two burr holes used for the stereotactic 
injection. This is thus a valid and higher resolution endpoint alternative to in vivo µMRI, the current standard 
modality for visualizing the intact brain ventricular system but unable to capture the cranium.
ViceCT can be subsequently complemented with whiceCT to assess brain morphology. WhiceCT is based on 
diceCT, the technique where different structures become enhanced on µCT through immersion of the sample 
in Lugol’s solution and diffusion of iodine into the tissues. WhiceCT extends diceCT capabilities by optimizing 
the visualization of brain parenchyma with minimal shrinkage, while maintaining the craniofacial structures 
intact (Fig. 3). This approach enabled for the first time the simultaneous acquisition and analysis of the detailed 
brain anatomy and gross craniofacial structures with fast, high-resolution µCT. After careful removal of all the 
soft tissues surrounding the skull, detailed analysis of craniofacial structures can also be achieved by whiceCT, 
at a comparable level as viceCT (Fig. 6). Regarding the mouse brain, the whiceCT protocol allowed the detailed 
visualization of specific internal structures, such as the cerebellum, cortex and olfactory bulbs, and has the poten-
tial to deliver ultra-detailed images of the brain using even higher resolution µCT. We illustrated here that this 
allows the evaluation of smaller structures or layers of interest with even greater detail, such as the Ammon’s horn, 
dentate gyrus or corpus callosum (Fig. 4). WhiceCT offers a better, high image quality and low-cost alternative 
with shorter scanning time compared to the current state-of-the-art that requires acquiring and co-registering 
a several hour-long ex vivo µMRI and a µCT scan to visualize skeletal structures.
A drawback of whiceCT may be that the incubation time is prolonged to 18 days, as compared to diceCT 
protocols for mouse brain imaging that report only 1–2 days incubation to reach homogeneous contrast enhance-
ment 30–32. However, this incubation time is within an acceptable range, since more recent techniques employing 
PTA-enhanced µCT optimized for embryonic and early postnatal mice require even longer incubation periods 
in adult mice 34. The advantage of the whiceCT protocol that outweighs the relatively long incubation time is that 
the craniofacial structure is conserved. Regarding brain size comparisons, we found a smaller cerebellar volume 
derived from whiceCT in comparison to µMRI, which could be attributed to some degree of shrinkage specifi-
cally affecting this brain region during sample processing (Fig. 3, C). To assess the bias between both modalities, 
differences in resolution should also be considered, as µCT provides a much more accurate measure due to the 
27.6 times smaller voxel size in our case, making whiceCT more precise.
To assess the possibility to visualize both the brain parenchyma and the ventricles simultaneously in the 
same scan, we observed that after performing the viceCT, the Lugol’s solution did not remain long enough in the 
brain ventricles to combine it with the long sample incubation required for whiceCT. However, it is possible to 
combine both protocols in a convenient working pipeline as a mouse can be anaesthetized to perform the viceCT 
protocol and after scanning, the head can be extracted to start immediately after the whiceCT protocol. The burr 
holes for the stereotactic injection actually enhance contrast diffusion for whiceCT. To illustrate this, we applied 
our vice- and whiceCT pipeline to evaluate genotype and pharmacological effects on the craniofacial and brain 
systems in a mouse model of Down syndrome (Fig. 7). We were able to demonstrate the capability of vice- and 
whiceCT to detect and quantify differences in the volume of the brain, the ventricles and the cerebellum, as well 
as in the skull shape applying Geometric Morphometrics on the high-resolution µCT.
Figure 8.  Overview of the applications of µMR and µCT-based imaging for brain and skull analysis. Left 
column shows the imaging modality and optional use in a sample processing and imaging pipeline. Central 
column shows the structures that can be analyzed using such modality independently. Right column 
summarizes the readouts that can be obtained using the different modalities and combinations thereof.
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Conclusions and future directions. Typically, to visualize the brain and the skull simultaneously, it is 
necessary to perform a co-registration of µMRI and µCT. µMRI can deliver great contrast in the brain but is 
unable to visualize the skeleton, whereas µCT can visualize the skeleton together with the fat and lungs, but is 
unable to visualize the brain. In comparison to existing techniques, viceCT and whiceCT need only a single µCT 
scan to visualize the brain (whiceCT) or the ventricles (viceCT) ex vivo, maintaining the anatomical context 
of the brain anatomy and ventricles within the cranium (Fig. 8). Although it is still necessary to co-register the 
µCT scans if the brain parenchyma needs to be visualized together with the ventricles, our approach represents a 
step forward on simultaneous imaging of the brain and the skull (Fig. 8). An additional asset is that viceCT and 
whiceCT would allow destaining of the sample using sodium thiosulfate and performing histology after imaging 
25,57. In future work, further improvements to the procedures could envisage the use of hyper-high resolution 
scans (≈ 1 µm) and post-hoc optimization with software for contrast enhancement such as ANKAphase 58. In 
addition, different concentrations of iodine, or different temperatures during incubation could be tested to fur-
ther optimize the contrast and incubation time for samples with completely intact craniofacial anatomy.
We envisage a wide array of possible applications where this novel methodology covers an unmet need, such 
as when planning for targeting a specific brain region with stereotactic injection, which currently needs a brain 
µMRI co-registered with a skull µCT as a reference 18,59,60. Other examples where viceCT and/or whiceCT could 
be instrumental are phylogenetic and evolutionary studies 27, as well as studies in neuroscience research that 
involve precise phenotyping and experimental procedures with (transgenic) animal models of neurodevelop-
mental disorders with simultaneous affectation of the brain and craniofacial structure.
Methods
Animals and ethical statement. Wildtype (WT) mice from the KU Leuven animal facilities were used 
for experiments. Trisomic mice and euploid littermates were obtained from our in-house breeding colony, estab-
lished from WT male and Ts65Dn females (refs. 001875 and 001924, the Jackson Laboratory Bar Harbor, ME, 
USA). The date of conception (E0) was determined as the day in which a vaginal plug was present. We bred 
two litters, one of which was administered with GTE-EGCG (Mega Green Tea Extract, Life Extension, USA) 
via drinking water at a concentration of 0.09 mg/mL. Epigallocatechin gallate (EGCG) crosses the placenta and 
reaches the  embryo61. The treatment started prenatally at embryonic day 9 (E9) via the drinking water of the 
pregnant dams, and continued until the mice were scanned at 7 months of age. In total, 14 mice were generated 
and genotyped by PCR from ear snips. The mice were allocated in groups according to their genotype and phar-
macological intervention (WT and TS, untreated and treated), which included four animals per group except 
in the TS untreated group, in which only one mouse survived. Mice were housed at the animal facility of KU 
Leuven in standard individually ventilated cages (40 cm long × 25 cm wide × 20 cm high) under a 12 h light/
dark schedule in controlled environmental conditions of humidity (50–70%) and temperature (22 ± 2 °C) with 
food and water supplied ad libitum. Water intake was monitored by cage. All procedures complied with all local, 
national and European regulations and were authorized by the Animal Ethics Committee of KU Leuven (ECD 
approval number P004/2016).
Contrast agent. Lugol’s solution was purchased from Sigma Aldrich (St. Louis, USA), with a concentration 
of (KI) 0.67–0.71% and (I) 0.33–0.37%.
Transcardial perfusion. Adapting the protocol described in 62, mice were terminally anesthetized using 
3 µL/g of Dolethal (0.2  mg/µL pentobarbital, Vétoquinol) until no twitch response was obtained from a toe 
pinch. After sedation, each mouse was secured in supine position by gently taping the forepaws and hind paws 
to a pintable inside a chemical fume hood. Then, an incision was made through the skin with surgical scissors 
along the thoracic midline from just beneath the xiphoid process up to the clavicle. Two additional skin incisions 
were made from the xiphoid process along the base of the ventral ribcage laterally. Next, the two skin flaps were 
reflected rostrally and laterally to completely expose the thoracic field, and the xiphoid process was grasped with 
blunt forceps and raised slightly to insert pointed scissors. The thoracic musculature and ribcage were then cut 
between the breastbone and medial rib insertion points and the incision was extended rostrally to the level of the 
clavicles. Afterwards, the diaphragm was separated from the chest wall on both sides with scissor cuts, and the 
reflected ribcage was pinned with 18G needles to expose the heart and the rest of thoracic organs. Then, a 24G 
needle was inserted in the left ventricle. Immediately after, the right atrium was cut with scissors and infusion 
began at the first sign of blood flow.
Mice were perfused using saline, paraformaldehyde (PFA, 4% in PBS) and Lugol’s solution. To remove the 
blood from the mouse, we first perfused saline until the fluid exiting the right atrium was entirely clear (step 
1); then, we perfused 20 to 30 mL of PFA to fix the tissue (step 2); and finally, to increase the contrast of the soft 
tissues, we perfused Lugol’s solution until the liver and paws were colored (step 3). The perfusion steps were 
optimized and altered according to Supplementary Table S1.
WhiceCT sample preparation. Mouse heads were extracted by decapitation several vertebrae below the 
base of the skull. Then, two burr holes were drilled in the skull to facilitate diffusion (a step not necessary if per-
formed after viceCT, as two drill holes are already present from the stereotactic injection). Next, the heads were 
fixed in 4% PFA at 4 °C and the soft tissue of the head was removed. Then, the samples were incubated in Lugol’s 
solution in 50 mL centrifuge tubes at 4 °C throughout sample processing.
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Stereotactic injection for viceCT. Mice were terminally anesthetized with an intra-peritoneal injection 
of 3 µL/g of Dolethal and were placed in a stereotactic head frame (Stoelting, Wood Dale, IL, USA) for stereo-
tactic injections as described before 59, with minor adaptations. The skull was exposed via a midline incision in 
the skin. The skull flat position was achieved by placing bregma and lambda in the same horizontal plane by 
adjusting the vertical tooth bar. One or two burr holes were made at the planned entry location depending on 
the experimental approach. Next, a 30 G needle loaded with contrast fluid (U-100, Terumo, Leuven, Belgium) 
was mounted on the stereotactic arm, positioned at bregma and then translated antero-posteriorly and medio-
laterally along to the planned trajectory to target the right (coordinates (mm): antero-posterior (AP): − 0.2; 
medio-lateral (ML): − 1.0; dorso-ventral (DV): − 1.8)) and left (coordinates (mm): antero-posterior (AP): − 0.2; 
medio-lateral (ML): + 1.0; dorso-ventral (DV): − 1.8)) lateral ventricles. Finally, after perforation of the dura 
mater, the needle was lowered until reaching the planned coordinates in a single motion in approximately ten 
seconds. After injection, the needle was kept in place for a minute to allow liquid deposition, and then gently 
removed from the brain.
For the unilateral approach, a stereotactic injection of 100 or 50 µL was performed in the right lateral ventricle 
with an injection rate of 0.33 µL/s and an injection time of 2 min 30 s. For the bilateral injection approach, 40 µL 
was injected in each of the lateral ventricles with an injection rate of 0.22 µL/s and an injection time of 3 min.
Micro‑computed tomography (µCT). Whole-body mice or heads (in batches of 3) were scanned with the 
SkyScan 1278 (Bruker Micro-CT, Kontich, Belgium) using the optimized parameters specified in Supplementary 
Table S2. For the ultra-high-resolution scan, the heads were individually maintained in a humid environment by 
placing two sources of water next to the sample and covering it with parafilm to avoid the sample from drying 
and consequent shrinking, and scanned using the SkyScan 1076 (Bruker Micro-CT, Kontich, Belgium).
Micro‑magnetic resonance (µMR). In vivo µMRI measurements were performed using a 9.4 T Bruker 
Biospec small animal µMR scanner (Bruker Biospin, Ettlingen, Germany; 20  cm horizontal bore) equipped 
with actively shielded gradients (600 mT  m−1). A quadrature radio-frequency resonator (inner diameter 7.2 cm, 
Bruker Biospin) was used for transmission of radiofrequency pulses and decoupled to a brain surface coil (quad-
rature shaped surface coil optimized for mouse brain scanning, Bruker Biospin). In  vivo anatomical images 
were obtained through a 3D T2 weighted RARE sequence (TR/TE: 1,500/ 43.44 ms; RARE factor: 16; FOV: 
20 × 20 × 20  mm3; matrix 128 × 128 × 128; acquisition time 20 min).
Ex vivo µMRI images were acquired four days after performing a transcardial perfusion with a 10 mM 
Gd-DTPA solution, following a previously published protocol 63. The images were acquired using a 3D FLASH 
pulse sequence: 11 ms TE, 75 ms TR, 1.6 × 3.2 × 1.6 cm FOV, 256 × 512 × 256 matrix yielding 62.5 μm isotropic 
resolution, 4 averages, 1 repetition resulting in a total acquisition time of 12 h 17 min.
Density calibration and image quality assessment. To convert grey values into Hounsfield units 
(HU), the mean gray value within a volume of interest (VOI) of ten slices placed in the ventricles or the paren-
chyma (CTAn software, Bruker Micro-CT, Kontich, Belgium) was converted from a calibration line obtained 
from scanning a water-in-air phantom using the same settings, in which the mean gray value of air was set to 
− 1,000 HU and the mean gray value of water to 0 HU.
The signal to noise ratio (SNR) for viceCT was computed in CTAn by calculating the ratio between the mean 
gray value within a VOI of ten slices placed in the ventricles or the parenchyma and the standard deviation of the 
same VOI. For the µMR images, SNR was calculated as the mean gray value of the ventricle or the parenchyma 
divided by the standard deviation of the background noise. The mean gray value of the brain ventricles and the 
brain parenchyma were computed by the weighted average of the mean gray value within a region of interest 
(ROI) placed in those regions in five slices. The standard deviation of the background noise was computed as 
the weighted average of the standard deviation within an ROI placed in the background in five slices multiplied 
by 1.53, to adjust for the differences in the Rayleigh noise distribution.
The contrast to noise ratio (CNR) was computed in CTAn from viceCT data by calculating the difference in 
mean gray value within a VOI of ten slices placed in the ventricles and the mean gray value within a VOI of ten 
slices placed in the parenchyma and dividing it by the standard deviation of the VOI placed in the parenchyma. 
For the µMR images, CNR was calculated as the difference between the mean gray value of the ventricle and the 
parenchyma, divided by the standard deviation of the background noise, computed as explained above.
Data processing. To segment the brain, ventricles and cerebellum, the µMRI data were first converted to 
Analyze file format using ImageJ (1.52d, National Institute of Health), then loaded into Amira (v5.2.1, Visualiza-
tion Sciences Group, FEI) together with the µCT data. Then, each region was manually segmented by drawing a 
region of interest covering those structures on each image slice and the volume reported.
Statistical analysis. We performed all the statistical tests using GraphPad Prism (v5.04, GraphPad Soft-
ware, San Diego, California USA).
The Bland Altman test is a method to quantify the agreement between two quantitative measurements 64. In 
this method, the bias between two measured volumes is established as the average of the difference between the 
volumes measured by the two methods. The limits of agreement are estimated as the 95% limits of agreement 
based on the standard deviation of the bias. The mean volume of the analyzed structure was calculated as the mean 
of all the measurements taken with both µMRI and µCT. The percentage shift of the bias was estimated as the ratio 
between the bias over the mean volume of the analyzed structure, as Bias(average difference between two techniques)Mean volume of the analyzed structure × 100 . 
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The percentage shift associated with the upper and lower 95% limits of agreement was estimated using the same 
formula but using in the numerator the scores of the upper and lower limits calculated from the standard devia-
tion of the bias. These values indicated the range of variation of the percentage shift in individual measurements 
between the two methods.
Uncorrected Dunn’s test was used to assess if the difference in the volume of the whole brain, cerebellum and 
ventricles were significant.
Shape analysis. We quantitatively compared the skull morphology of WT mice with and without GTE-
EGCG and TS treated mice using a quantitative shape analysis 65. The analysis was based on the 3D coordinates 
of 27 anatomical skull landmarks registered using Amira on the µCT isosurfaces obtained from the viceCT 
protocol (Supplementary Figure S6). To assess shape variation we performed a Generalized Procrustes Analysis 
(GPA) followed by a Principal Component Analysis (PCA) using MorphoJ 66. Skull shape variation was assessed 
by creating a morphospace based of the two first PCs, which explain the largest percentages of morphological 
variation within the sample.
Data availability
Because of data size, data is available upon simple reasonable request to the corresponding author.
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